Polymorphism rs662 of the PON1 gene (Q192R) in patients with chronic hepatitis c and metabolic syndrome
DOI: 10.32364/2587-6821-2025-9-12-2
A.A. Koklyushkina, M.S. Bokhonov, I.G. Sitnikov
Yaroslavl State Medical University, Yaroslavl, Russian Federation
Background: in patients with chronic hepatitis C (CHC), the presence of comorbid pathology—components of the metabolic syndrome (MS), including type 2 diabetes mellitus (T2DM), obesity, and cardiovascular diseases — is of great interest. Genetic predictors influencing comorbidity in CHC patients are currently being examined. The rs662 polymorphism of the PON1 gene (Q192R) attracted attention in this context.
Aim: to investigate the association of the rs662 polymorphism of the PON1 gene (Q192R) with MS in patients with CHC.
Patients and Methods: the study included 124 patients with CHC and MS. The diagnosis of CHC infection was established when patients presented with RNA of the hepatitis C virus for 6 months or more. The rs662 polymorphism of the PON1 gene (Q192R) was tested using real-time polymerase chain reaction (PCR) on an iCycler iQ5 (BioRad) instrument with the "SNP-express-PB" reagent kit.
Results: analysis of the distribution of PON1 gene genotypes showed that the genotype QQ (n=62; 50%), heterozygous genotype QR (n=22; 17.8%) and homozygous RR (n=40; 32.2%) were recorded. In CHC patients, the RR and QR genotypes of the PON1 gene are associated with higher risks of developing obesity, T2DM, dyslipidemia, and arterial hypertension (AH). No association with metabolic disorders was found in patients carrying the QQ genotype.
Conclusion: identifying individual genetic characteristics of patients at early stages will allow for the application of effective preventive measures aimed at preventing the development of comorbid pathology and improving the quality of life for CHC patients.
Keywords: hepatitis, metabolic syndrome, obesity, diabetes mellitus, genes, PON1.
For citation: Koklyushkina A.A., Bokhonov M.S., Sitnikov I.G. Polymorphism rs662 of the PON1 gene (Q192R) in patients with chronic hepatitis c and metabolic syndrome. Russian Medical Inquiry. 2025;9(12):840–845 (in Russ.). DOI: 10.32364/2587-6821-2025-9-12-2
ABOUT THE AUTHORS:
Anastasiia A. Koklyushkina — Assistant Professor of the Department of Infectious Diseases, Epidemiology and Pediatric Infections, Yaroslavl State Medical University; 5, Revolutsionnaya str., Yaroslavl, 150000, Russian Federation; ORСID iD 0009-0002-7673-5823
Maksim S. Bokhonov — C. Sc. (Med.), Associate Professor of the Department of Infectious Diseases, Epidemiology and Pediatric Infections, Yaroslavl State Medical University; 5, Revolutsionnaya str., Yaroslavl, 150000, Russian Federation; ORСID iD 0000-0003-0611-7325
Ivan G. Sitnikov — Dr. Sc. (Med.), Professor, Head of the Department of Infectious Diseases, Epidemiology and Pediatric Infections, Yaroslavl State Medical University; 5, Revolutsionnaya str., Yaroslavl, 150000, Russian Federation; ORСID iD 0000-0002-2821-433X
Contact information: Anastasiia A. Koklyushkina, e-mail: nastya.koklyushkina.93@mail.ru
Financial Disclosure: the authors have no a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 15.08.2025.
Revised 09.09.2025.
Accepted 02.10.2025.
2. Kaput J., Noble J., Hatipoglu B. et al. Application of nutrigenomic concepts to Type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2007;17(2):89–103. DOI: 10.1016/j.numecd.2006.11.006
3. Ткаченко Л.И. Клинико-патогенетическая роль нарушений углевод-ного и липидного обмена у больных хроническими вирусными гепатитами: прогнозирование и оптимизация терапии: автореф. дис. … д-ра мед. наук. Ставрополь; 2016.Tkachenko L.I. Clinical and Pathogenetic Role of Disorders of Carbohydrate and Lipid Metabolism in Patients with Chronic Viral Hepatitis: Prediction and Optimization of Therapy: thesis. Stavropol, 2016 (in Russ.).
4. Nahon P., Bourcier V., Layese R. et al. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology. 2017;152(1):142–156.e2. DOI: 10.1053/j.gastro.2016.09.009. Erratum in: Gastroenterology. 2021;161(1):377. DOI: 10.1053/j.gastro.2019.02.029
5. Younossi Z.M., McCullough A.J. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int. 2009;29 Suppl 2:3–12. DOI: 10.1111/j.1478-3231.2008.01949.x. Erratum in: Liver Int. 2009;29(4):617. PMID: 19187068
6. Rosenblat M., Gaidukov L., Khersonsky O. et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem. 2006;281:7657–7665. DOI: 10.1074/jbc.M512595200
7. Aviram M., Rosenblat M., Bisgaier C.L. et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possibleperoxidative role for paraoxonase. J Clin Invest. 1998;101:1581–1590. DOI: 10.1172/JCI1649
8. Rosenblat M., Karry R., Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis. 2006;187:74–81. DOI: 10.1016/j.atherosclerosis.2005.08.026
9. Sampson M.J., Braschi S., Willis G., Astley S.B. Paraoxonase-1 (PON-1) genotype and activity and in vivo oxidized plasma low-density lipoprotein in Type II diabetes. Clin Sci (Lond). 2005;109(2):189–197. DOI: 10.1042/CS20050089
10. Berrougui H., Momo C.N., Khalil A. Health benefits of high-density lipoproteins in preventing cardiovascular diseases. J Clin Lipidol. 2012;6(6):524–533. DOI: 10.1016/j.jacl.2012.04.004
11. Costa L.G., Giordano G., Furlong C.E. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol. 2011;81(3):337–344. DOI: 10.1016/j.bcp.2010.11.008
12. Précourt L.P., Amre D., Denis M.C. et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis. 2011;214(1):20–36. DOI: 10.1016/j.atherosclerosis.2010.08.076
13. Mirdamadi H.Z., Sztanek F., Derdak Z. et al. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol. 2008;66(3):366–374. DOI: 10.1111/j.1365-2125.2008.03213.x
14. Ким М.В., Скорюкова С.А., Быстрова А.А. и др. Полиморфизм Q192R гена параоксаназы у больных сахарным диабетом 2 типа. Ученые записки Первого Санкт-Петербургского государственного медицинского университета имени академика И.П. Павлова. 2014;21(2):69–72. DOI: 10.24884/1607-4181-2014-21-2-69-72Kim M.V., Skoryukova S.A., Bystrova A.A. et al. Q192R polymorphism of the paraoxonase gene in patients with type 2 diabetes mellitus. Scientific Notes of the First Pavlov First Saint Petersburg State Medical University. 2014;21(2):69–72 (in Russ.). DOI: 10.24884/1607-4181-2014-21-2-69-72
15. Войтович А.Н., Богданова М.А., Смирнов Б.И. и др. Нарушения липидного обмена, активность параоксаназы 1 и полиморфизм L55M и Q192R в гене параоксаназы 1 у больных ишемической болезнью сердца. Артериальная гипертензия. 2010;16(6):569–575. DOI: 10.18705/1607-419X-2010--6-Voitovich A.N., Bogdanova M.A., Smirnov B.I. et al. Lipid metabolism disorders, paraoxonase 1 activity, and L55M and Q192R polymorphisms in the paraoxonase 1 gene in patients with coronary artery disease. Arterial hypertension. 2010;16(6):569–575 (in Russ.). DOI: /10.18705/1607-419X-2010--6-
16. Федорова А.П., Серебрякова О.В., Серкин Д.М. и др. Ассоциации генетических полиморфизмов GLN192ARG PON1 И С3238G APOC3 у женщин с ишемической болезнью сердца на фоне сахарного диабета 2 типа и гипотиреоза. Архивъ внутренней медицины. 2017;7(4):271–277. DOI: 10.20514/2226-6704-2017-7-4-271-277Fyodorova A.P., Serebryakova O.V., Serkin D.M. et al. Associations of genetic polymorphisms GLN192ARG PON1 and C3238G APOC3 in women with coronary heart disease against type 2 diabetes mellitus and hypothyroidism. Archive of Internal Medicine. 2017;7(4):271–277 (in Russ.). DOI: 10.20514/2226-6704-2017-7-4-271-277
This work is licensed under a Creative Commons «Attribution» 4.0 License.
